Document is current
Any future updates will be listed below
-
Authors
Cherian, Kirsten N.
Keynan, Jackob N. http://orcid.org/0000-0001-8376-3406
Anker, Lauren http://orcid.org/0000-0002-6153-217X
Faerman, Afik
Brown, Randi E.
Shamma, Ahmed
Keynan, Or
Coetzee, John P.
Batail, Jean-Marie
Phillips, Angela
Bassano, Nicholas J.
Sahlem, Gregory L.
Inzunza, Jose
Millar, Trevor
Dickinson, Jonathan http://orcid.org/0000-0001-9203-0730
Rolle, C. E.
Keller, Jennifer
Adamson, Maheen
Kratter, Ian H. http://orcid.org/0000-0001-9122-4525
Williams, Nolan R. http://orcid.org/0000-0003-4368-3203
-
Funding
Funding for this research was provided by:
Steve and Genevieve Jurvetson and the Sergey Brin Family Foundation
- License Information
-
More Information
Article History
Received: 8 May 2023
Accepted: 10 November 2023
First Online: 5 January 2024
Competing interests
: N.R.W. and I.H.K. are inventors on a patent application (no. 18/467,324) related to the safety of MISTIC administration as described in the paper. J.P.C. and N.R.W. are inventors on a patent application (no. 18/467,343) related to the use of ibogaine to treat disorders associated with brain aging. J.D., J.I. and T.M. are shareholders in Ambio Life Sciences, which offers ibogaine treatments. J.D, J.I. and T.M. are inventors in a related provisional patent application no. 63/523,774. The application is related to adjunct treatment with various compounds during ibogaine therapy to improve safety. J.D. is founder of Terragnosis, Inc., a company dedicated to the sourcing and semisynthetic conversion of ibogaine precursors to ibogaine. The other authors declare no competing interests.
